Fosun Pharma's new adaptation to Avalanco Pak has been approved for the near future start-up of Phase III clinical practice.

On October 13, Fosun Pharma announced that its new drug, Malay acid avalanthepa tablets, had been approved by NMPA for clinical trials for chronic immunocompetitive plateroid reduction in adults (ITP).
Pharma intends to conduct phase III clinical trials in China after the near-term conditions are in place.
Avaquopopa is a plate plateatoprene-producing agent (TPO-R) agonist that was first approved for the domestic market in April 2020 and is adaptive to plateiac reduction (CLDT) associated with adult chronic liver disease patients with diagnostic or surgical procedures.
In March 2018, Fosun Pharma, a subsidiary of Fosun Pharma, and AkaRx, a subsidiary of Dova, reached an agreement to obtain exclusive development and commercial rights in Chinese mainland and Hong Kong, China, in the form of down payments, mileage payments, and a fixed amount of transfer delivery costs.
as of September 2020, Fosun Pharma's cumulative research and development investment in the new drug at this stage is approximately RMB105.99 million (unaudited; including licensing transfer fees).
As of the date of the announcement, adult patients with chronic liver disease-related plateroid reduction, which is suitable for diagnostic operation or surgery, have been listed in the United States, the European Union and China, and chronic immunocompetitive plateroid reduction (ITP) has been listed in the United States.
In addition, the new drug for thyroid reduction (CIT) caused by chemotherapy oncology has recently completed the International Multi-Center Phase III clinical trial, the preliminary analysis of the results of the trial did not reach the preset main composite endpoint, according to which Fosun Pharma will further evaluate and determine the adaptive disease in China's clinical development strategy, optimize clinical trial design and determine the registration strategy.
currently, TPO-R astrations are a routine treatment for plate plate plate reduction.
, except for Avalanco Pompeia, only Novarian's Aiqupopa was approved for listing.
2019, Avalanpa's global sales were $1,416 million, up 21% year-on-year, with domestic sales of about $2.77 million in 2018, and Avalanco's 2019 global sales were about $3.43 million.
addition, it is worth mentioning that Hengrui's TPO-R astration Class 1 new drug, Haiqupopa, was also submitted for listing in June 2020 and was formally incorporated into the priority review review on 25 July.
.